What triggers antitrust review in pharma M&A?

The FTC reviews pharma deals exceeding HSR thresholds (currently $111.4M). Key concerns include overlapping therapeutic areas, pipeline competition (even pre-clinical), and vertical integration between manufacturers and PBMs or distributors. The FTC has blocked or required divestitures in 40% of reviewed pharma deals since 2020.